title: SATB1 collaborates with loss of p16 in cellular transformation.
abstract: Tumor progression is associated with invasiveness and metastatic potential. The special AT-rich binding protein 1 (SATB1) has been identified as a key factor in the progression of breast cancer cells to a malignant phenotype and is associated with progression of human tumors. In normal development, SATB1 coordinates gene expression of progenitor cells by functioning as a genome organizer. In contrast to progenitor and tumor cells, SATB1 expression in nontransformed cells is not compatible with proliferation. Here we show that SATB1 expression in mouse embryonic fibroblasts induces cell cycle arrest and senescence that is associated with elevated p16 protein levels. Deletion of p16 overcomes the SATB1-induced senescence. We further provide evidence for an interaction of SATB1 with the retinoblastoma (RB)/E2F pathway downstream of p16. A combined deletion of the RB proteins, RB, p107 and p130 (triple-mutant; TM), prevents SATB1-induced G1 arrest, which is restored upon the reintroduction of RB into SATB1-expressing TM fibroblasts. SATB1 interacts with the E2F/RB complex and regulates the cyclin E promoter in an E2F-dependent manner. These findings demonstrate that p16 and the RB/E2F pathway are critical for SATB1-induced cell cycle arrest. In the absence of p16, SATB1 causes anchorage-independent growth and invasive phenotype in fibroblasts. Our data illustrate that p16 mutations collaborate with the oncogenic activity of SATB1. Consistent with our finding, a literature survey shows that deletion of p16 is generally associated with SATB1 expressing human cell lines and tumors.
authors.affiliation: 1] Institut Pasteur de Montevideo, Epigenetics of Cancer and Aging Laboratory, Montevideo, Uruguay [2] Research Institute of Molecular Pathology, Vienna, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Agrelo
authors.forename: H
authors.initials: H
authors.lastname: Kishimoto
authors.forename: M
authors.initials: M
authors.lastname: Novatchkova
authors.forename: V
authors.initials: V
authors.lastname: Peraza
authors.forename: M
authors.initials: M
authors.lastname: Paolino
authors.forename: A
authors.initials: A
authors.lastname: Souabni
authors.forename: A
authors.initials: A
authors.lastname: Wutz
mesh_terms: D000818:Animals; D002453:Cell Cycle; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic; D016922:Cellular Senescence; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000172:deficiency* / Q000235:genetics; D050684:E2F Transcription Factors / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D036961:Matrix Attachment Region Binding Proteins / Q000378:metabolism*; D051379:Mice; D009154:Mutation; D012175:Retinoblastoma / Q000473:pathology
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D050684:E2F Transcription Factors; D036961:Matrix Attachment Region Binding Proteins; C076189:SATB1 protein, human